🔗 Share this article

While the United States proceeds with historic adjustments to its vaccine recommendations, an unexpected name has emerged in a surprising turn: Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines throughout the pandemic and has focused upon potential deaths following Covid immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Health officials were set to announce radical revisions to the childhood immunization program in December, bringing the US with the Danish immunization schedule, sources say – a major change that would put the US at odds with much of the world with insufficient data for public health gain. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this calendar year.

A New Direction at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting certain childhood immunization guidelines in the US to become more in line with the Danish model, a nation with nationalized medicine and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been standard for former heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who ran CBER have had.”

CDER has an vast portfolio at the agency, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and so forth, and every single one have to be looked after,” she noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant management component to the position, which manages more than 5,000 personnel. “It’s a massive management job, if you perform it correctly,” the former official said.

Response and Controversial Initiatives

When asked about inquiries about Høeg’s credentials and whether this selection indicates more teamwork among FDA leaders on vaccines, a representative said that the “inquiries rely on inaccurate premises”.

“This background is consistent with the responsibilities of her role,” the spokesperson said, citing the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s new expedited review system, a contentious one-day drug-approval program that allegedly worried her preceding directors. “By what process are these medications being selected for this voucher program? Who takes the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he stated, “the FDA looks to be trending towards less stringent regulations of all drugs, aside from shots.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, history, some experts said. She authored a study using unconfirmed public submissions to estimate the incidence of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the current administration encompassed revising regulations for recently developed shots and halting “unnecessary” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She’s an thorough true believer who commences with her conclusions and tailors the evidence to retrofit the science in a highly disingenuous, fraudulent fashion,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|